MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Psychogenic movement disorders(PMD): Treatment"

  • 2019 International Congress

    A flowchart algorithm for the neurologist to discuss and attend sexual issues in Parkinson’s disease

    G. Bronner, S. Hassin-Baer, AD. Korczyn, T. Gurevich (Ramat-Gan, Israel)

    Objective: To propose guidelines for neurologists to discuss sexual issues and offer education and practical solutions. Background: Sexual dysfunction (SD) is a common nonmotor symptom…
  • 2018 International Congress

    Neuropsychiatric disorders in observed patients with Parkinson’s disease

    S. Lukmonov, D. Tolibov (Tashkent, Uzbekistan)

    Objective: Parkinson's disease (PD), - chronic progressive disease of the brain from the degeneration of the nigrostriatal neurons in the basal ganglia and impaired function.…
  • 2017 International Congress

    Treatment of Functional Neurological Disorders: Towards Expert Consensus Led Guidelines for the American Neuropsychiatric Association Committee for Research

    O. Ghaffar, M. Modirrousta, C. LaFrance, N. Williams, R. Shura, S. Ducharme, V. Voon (Whitby, ON, Canada)

    Objective: To develop evidence-based, expert consensus recommendations for the treatment of functional neurological disorders (FND) on behalf of the ANPA Committee for Research. Background: FND…
  • 2017 International Congress

    Botulinum Neurotoxin (BoNT) for treatment of functional (psychogenic) jerky movement disorders: a randomized placebo-controlled clinical trial

    Y. Dreissen, J. Dijk, J. Gelauff, E. Zoons, M. Contarino, R. Zutt, B. Post, D. van Poppelen, A. Munts, J. Speelman, R. de Haan, J. Koelman, M. Tijssen (Amsterdam, Netherlands)

    Objective: To assess the effectiveness of botulinum neurotoxin (BonT) in patients with functional jerky movement disorders Background: At least 2–9% of patients seen in movement…
  • 2016 International Congress

    Attention to action: Common to both conversion (psychogenic) and Parkinsonian (neurogenic) motor speech disorders

    S. Sapir (Haifa, Israel)

    Objective: To review and present a common abnormality --- attention to action--- underlying Parkinsonian and conversion speech disorders. Background: Conversion speech disorders are characterized by…
  • 2016 International Congress

    Cognitive behavioural thrapy and adiunctive physical therapy for functional movement disorders

    R. Erro, M. Tinazzi, C. Dallocchio (London, United Kingdom)

    Objective: To test the feasibility and efficacy of Cognitive Behavioural Therapy (CBT) and Adjunctive Physical Therapy (APA) APA in Functional Movement Disorders (FMD). Background: Functional…
  • 2016 International Congress

    Transcranial versus root repeated magnetic stimulation as a treatment of psychogenic movement disorders

    B. Garcin, C. Hubsch, L. Lliescu, L. Naccache, M. Vidailhet, E. Fournier, F. Mesrati, E. Roze, B. Degos (Paris, France)

    Objective: To determine whether the beneficial effect of repeated transcranial magnetic stimulation (rTMS) in psychogenic movement disorders (PMDs) is the consequence of a cortical functioning…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley